Overview

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
0
Participant gender:
All
Summary
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rochester General Hospital
Treatments:
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Rituximab
Criteria
Inclusion Criteria:

1. Diagnosis of B cell non-Hodgkin's lymphoma

2. Medically stable

3. Able to understand and willingness to sign a written informed consent

4. Able to comply with study procedures

Exclusion Criteria:

1. Previously diagnosed primary immunodeficiency

2. Additional immunosuppressive states

3. Ongoing therapy with Ig replacement